You are here
Eloxx Pharmaceuticals To Present at the 8th Orphan Drugs & Rare Diseases Congress, the Oppenheimer Fall Summit, and the 2018 Cantor Global Healthcare Conference
WALTHAM, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Robert E. Ward, Chairman and CEO of Eloxx, will be a participant at three upcoming conferences:
- On September 26, 2018, Mr. Ward will participate in a panel discussion titled: “Strategies for Implementing Value-Based Pricing and Reimbursement for Orphan Drugs” at the 8th Orphan Drugs & Rare Diseases Congress in Boston, Massachusetts, on Wednesday, September 26, 2018.
- On September 27, 2018, Mr. Ward and Mr. David Snow, Chief Business Officer of Eloxx, will host one-on-one meetings with investors at the Oppenheimer Fall Summit - Focused on Specialty Pharma and Rare Diseases at the Langham Hotel in New York City,
- Mr. Ward will make a presentation at the 2018 Cantor Global Healthcare Conference at the InterContinental New York Barclay Hotel where members of senior leadership will also host one-on-one meetings with investors. The presentation will be a live webcast and can be accessed from the link below or from the company’s website at www.eloxxpharma.com, where a replay will also be available.
Date: Tuesday, October 2, 2018
Time: 10:20 a.m.
Audio Webcast Link: http://wsw.com/webcast/cantor7/elox
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. Eloxx’s preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, including: the development of the Company’s read-through technology; the approval of the Company’s patent applications; the Company’s ability to successfully defend its intellectual property or obtain necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the Company’s ability to obtain applicable regulatory approvals for its current and future product candidates; the acceptance by the market of the Company’s products should they receive regulatory approval; the timing and success of the Company’s preliminary studies, preclinical research, clinical trials, and related regulatory filings; the ability of the Company to consummate additional financings as needed; as well as those discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.